@article{Devi_2022, title={Evalution of Anti-Arthritic Potential of Siddha Formulation ChanthirothayaMathirai on Freund‘s Adjuvant-Induced arthritis in Wistar rats}, volume={16}, url={https://asiapharmaceutics.info/index.php/ajp/article/view/4393}, DOI={10.22377/ajp.v16i2.4393}, abstractNote={<p>Introduction: Rheumatoid arthritis (RA) is an autoimmune, chronic multisystem disease with various systemic<br>manifestations resulting in joint damage and physical disability. The Siddha system of medicine is one of the<br>traditional system of Indian medicine, which comprises ennumber of siddha formulations for RA. The tablet<br>ChanthirothayaMathirai (CHTM), a herbomineral siddha formulation is found to be efficacious for RA. The<br>present study focuses on theevaluation of anti-arthritic potential of Siddha formulation CHTM on complete<br>Freund’s adjuvant (CFA)-induced arthritis model. Materials and Methods: The animals were grouped into three.<br>Group I received normal saline, Group II received 0.1 ml of CFA in the left hind and treated with 250 mg/kg of<br>CHTM from day 1 to 21, and Group III received 0.1 ml of CFA into the left hind and treated with 500 mg/kg of<br>CHTM from day 1 to 21. The biochemical parameters were carried out on all groups after 21 days. The presence<br>of any adverse effects was also recorded throughout the study. Results: A significant increase in the paw volume<br>and thickness of CFA-injected paws compared to the normal control paws was observed. Arthritic assessment<br>scoring revealed that CFA-injected paws were with the maximum scoring of 3.8. The treatment with CHTM at<br>both doses has significantly decreased arthritic scoring to 2.3. Results showed marginal signs of rejuvenation with<br>mild cartilages destruction with restoring histology of synovium and bone morphology were observed in low-dose<br>drug-treated rats. High-dose drug-treated rats showed normal histomorphology of synovium. Conclusion: The<br>study concluded that the trial drug CHTM at the dose of 250 and 500 mg/kg showed a significant reduction in joint<br>swelling with a reversal in bone and tissue morphology. Thus, CHTM formulation offers a strong protective effect<br>against Freund’s complete adjuvant-induced paw edema in rats. Hence, the drug CHTM has been scientifically<br>validated for its anti-arthritic potential in management of RA.</p>}, number={2}, journal={Asian Journal of Pharmaceutics (AJP)}, author={Devi, P. V. Sudhaa}, year={2022}, month={Jun.} }